Chronoscale Holdings Corp quarterly report, Q2 FY2018

Business context and reporting period

The supplied filing is Ekso Bionics Holdings, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2018; it is not a Chronoscale Holdings Corp. filing. Ekso develops and sells medical and industrial exoskeletons and provides engineering services. All financial amounts below are in U.S. dollars; financial statement amounts are in millions unless noted.

Financial results and condition

MetricQ2 2018Q2 2017Six months 2018Six months 2017
Revenue$2.967$1.867$5.486$3.303
Gross profit$0.967$0.396$1.736$0.748
Gross margin32.6%21.2%31.6%22.6%
Operating loss$(7.185)$(8.459)$(15.796)$(16.600)
Net loss$(7.978)$(5.507)$(15.877)$(13.809)
Net loss per share$(0.13)$(0.22)$(0.26)$(0.58)
  • Revenue growth was primarily driven by higher device sales, especially medical devices. Q2 device and related revenue increased 58%; first-half device and related revenue increased 67%.
  • Operating losses narrowed, but net losses increased year over year: Q2 reflected a $3.1 million warrant revaluation gain in 2017 versus a $0.2 million loss in 2018. First-half warrant gains were $0.5 million in 2018 versus $3.0 million in 2017. These noncash fair-value changes make net loss comparisons less reflective of operating performance.
  • Cash was $13.890 million at June 30, down from $27.813 million at year-end. Operating cash use was $12.804 million for the first half, versus $16.859 million in 2017; investing cash use was $0.031 million. Financing used $0.994 million, mainly for term-loan principal payments.
  • Current assets were $20.403 million and current liabilities $9.395 million; total assets were $23.208 million. Reported note payable was $6.079 million net of discounts and fees ($2.333 million current, $3.746 million noncurrent). The filing’s contractual-obligations table shows $6.875 million of term-loan payments.
  • Equity was $7.626 million and accumulated deficit was $160.031 million. Common shares outstanding were 60.832 million at June 30 and 60.832 million as of July 31, 2018.

Material changes versus the prior comparable period

  • Higher device sales lifted revenue and gross profit, while gross margin improved in both the quarter and first half.
  • Sales and marketing expense rose 20% in Q2 and 23% for the first half, reflecting increased clinical research activity and, in Q2, a $0.175 million charge for an abandoned German sales office. First-half expense also included severance.
  • Research and development expense fell 47% in Q2 and 42% for the first half, primarily due to lower employment costs following the May 2017 workforce reduction.
  • General and administrative expense rose 14% in Q2 and 31% for the first half. Reported drivers included severance and modified equity awards tied to executive departures, a supplier dispute settlement, and China business-development costs.
  • Cash declined by $13.923 million in the first half, compared with a $6.145 million decline in the first half of 2017; the prior period included $10.919 million of net equity and warrant proceeds.

Outlook, risks, contingencies and unusual items

  • Going concern and funding: Management stated that forecast cash is insufficient to fund operations for the twelve months after issuance, raising substantial doubt about the company’s ability to continue as a going concern. It estimated resources would cover obligations into the first quarter of 2019 and said significant additional financing is required. Financing may involve equity, debt, collaborations or warrant solicitations; availability and terms are uncertain, and equity financing could dilute shareholders. Without funding, substantial cost reductions or curtailed operations may be necessary.
  • Liquidity covenant: The debt agreement required $7.366 million of unrestricted cash at the latest June determination, recalculated monthly. The company reported compliance with this and other covenants at June 30; it estimated effective unrestricted cash at $6.524 million after accounting for the restriction.
  • Business plans: Management described continued investment in clinical and sales initiatives for rehabilitation, development and commercialization of a home-use exoskeleton, and industrial products. It is pursuing industrial sales through rental channels and manufacturer relationships. No quantified revenue or earnings guidance was provided.
  • Clinical and regulatory: The company reported 84 announced Ekso GT studies, including 53 completed and 31 ongoing, involving nearly 1,900 patients. Adoption, clinical outcomes, regulatory requirements, reimbursement and commercialization remain uncertain.
  • Commitments and litigation: Contractual obligations totaled $10.085 million, including $2.200 million of facility operating leases, $0.936 million of purchase obligations, and term-loan and capital-lease payments. The company disclosed three shareholder derivative actions alleging fiduciary-duty and related claims tied to alleged internal-control weaknesses; management considered them without merit and planned to defend them. It also disclosed earlier securities class actions referenced in its prior filings.
  • Other risks and changes: Management turnover was identified as a risk to operations, retention and institutional knowledge. Foreign-currency fluctuations affected reported other income/expense; the company said it does not hedge foreign-currency exposure. It adopted revenue-recognition Topic 606 using the modified retrospective method with no opening cumulative adjustment and no material effect on revenue timing or amount.

Important facts for investors to verify

  1. Whether Ekso secured financing sufficient to address the stated funding shortfall and going-concern uncertainty, and on what terms.
  2. Subsequent monthly covenant cash requirements, unrestricted cash, operating cash burn and actual runway relative to the first-quarter 2019 estimate.
  3. Whether device-sales growth and improved gross margins continued, particularly in medical versus industrial products, and whether growth translated into lower operating cash use.
  4. The progress and outcomes of clinical studies, regulatory status, customer adoption and the commercial performance of rental and industrial-sales channels.
  5. Developments in the derivative and securities litigation, management transitions, and any resulting costs or changes to controls.
  6. Potential dilution from financing, equity compensation, and outstanding options and warrants.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.